IBT
AMLX icon

International Biotechnology Trust’s Amylyx Pharmaceuticals AMLX Stock Holding History

International Biotechnology Trust’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		$5.4M Buy
295,000
+270,000
+1,080% +$5.71M 1.82% 19
2023
Q2 		$539K Buy
+25,000
New +$675K 0.16% 56

Other funds holding AMLX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

International Biotechnology Trust's AMLX Position: Q3 2023 in Review

International Biotechnology Trust increased its Amylyx Pharmaceuticals (AMLX) stake by 1,080% in Q3 2023, buying an estimated $5.71M and bringing the position to 295,000 shares worth $5.4M. The position accounts for 1.82% of the portfolio, ranked #19.

International Biotechnology Trust first reported a position in AMLX in Q2 2023 and has held it in 2 quarters since. 170 funds tracked by Wall St. Rank hold AMLX as of Q3 2023.

  • International Biotechnology Trust held 295,000 shares of Amylyx Pharmaceuticals worth $5.4M as of Q3 2023.
  • International Biotechnology Trust bought 270,000 Amylyx Pharmaceuticals shares in Q3 2023, an estimated $5.71M.
  • Amylyx Pharmaceuticals made up 1.82% of International Biotechnology Trust's portfolio in Q3 2023, its #19 holding.
  • International Biotechnology Trust first reported a position in Amylyx Pharmaceuticals in Q2 2023 and has held it in 2 quarters since.
  • 170 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q3 2023.

Based on International Biotechnology Trust's 13F filing for Q3 2023, filed 14 Nov 2023.